CAS |
50-55-5 |
Chinese Name |
利血平 |
English Name |
Reserpine |
Synonym |
Serpalan;Serpasil;Serpivite |
Unit |
Bottle |
Purity |
HPLC≥98% |
Molecular Formula |
C33H40N2O9 |
Molecular Weight |
608.68 |
Appearance |
White to off-white solid |
Storage |
Powder : 2-8℃, 2 years; In solvent(mother liquid): -20℃, 1 month; -80℃, 6 months |
Solubility |
Soluble in DMSO≥10mg/ml |
MDL |
MFCD00005091 |
EC |
EINECS 200-047-9 |
InChIKey |
QEVHRUUCFGRFIF-MDEJGZGSSA-N |
InChI |
InChI=1S/C33H40N2O9/c1-38-19-7-8-20-21-9-10-35-16-18-13-27(44-32(36)17-11-25(39-2)30(41-4)26(12-17)40-3)31(42-5)28(33(37)43-6)22(18)15-24(35)29(21)34-23(20)14-19/h7-8,11-12,14,18,22,24,27-28,31,34H,9-10,13,15-16H2,1-6H3/t18-,22+,24-,27-,28+,31+/m1/s1 |
PubChem CID |
5770 |
SMILES |
O=C([C@H]([C@@H](OC)[C@H](OC(C1=CC(OC)=C(OC)C(OC)=C1)=O)C[C@]2([H])CN3CC4)[C@@]2([H])C[C@]3([H])C5=C4C(C=CC(OC)=C6)=C6N5)OC |
Description |
Reserpine is an inhibitor of vesicular monoamine transporter 2 (VMAT2). |
Target Point |
VMAT2 |
Passage |
Membrane Transporter&Ion Channel |
Data Literature Source |
[1]. Antkiewicz-Michaluk L, et al. Withdrawal from repeated administration of a low dose of reserpine induced opposing adaptive changes in the noradrenaline and serotonin system function: a behavioral and neurochemical ex vivo and in vivo studies in the rat. Prog Neuropsychopharmacol Biol Psychiatry. 2015 Mar 3;57:146-54.
[2]. Hong B, et al. Reserpine Inhibit the JB6 P+ Cell Transformation Through Epigenetic Reactivation of Nrf2-Mediated Anti-oxidative Stress Pathway. AAPS J. 2016 May;18(3):659-69.
[3]. Sreemantula S, et al. Reserpine methonitrate, a novel quaternary analogue of reserpine augments urinary excretion of VMA and 5-HIAA without affecting HVA in rats. BMC Pharmacol. 2004 Nov 16;4:30. |
Specification |
20mg 100mg 10mM*1mL (in DMSO) |